FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2767476799> ?p ?o ?g. }

• W2767476799 endingPage "S2252" @default.
• W2767476799 startingPage "S2252" @default.
• W2767476799 abstract "AXL is a receptor tyrosine kinase that plays an important role in signal transduction in normal and malignant cells. Abnormal expression and/or activation of AXL can provide a survival advantage for certain cancer cells, and AXL up-regulation is associated with poor prognosis in several cancers. Recently, it has been reported that up-regulation of AXL expression represents a mechanism of EGFR-TKI resistance in EGFR-mutant non-small cell lung cancer. Kinase activity was measured by mobility shift assay. The inhibition of hGAS6-induced migration was measured in AXL-transfected NIH3T3 (NIH3T3-AXL) cells using a real-time cell analyzer (RTCA) DP instrument. The in vivo anti-tumor effects of DS-1205b mono- and combination-therapy with EGFR-TKI were evaluated in NIH3T3-AXL allograft and EGFR-mutant NSCLC (T790M-negative) HCC827 xenograft models. Protein expression was analyzed by Western blot or immunohistochemistry, and gene expression was analyzed by RT-PCR or RNA seq. DS-1205b selectively inhibited AXL kinase activity with IC50 of 1.3 nM, and with NIH3T3-AXL cells, DS-1205b inhibited hGAS6-induced migration in vitro with EC50 of 2.7 nM. DS-1205b monotherapy exerted significant antitumor activity including tumor regression in an NIH3T3-AXL allograft model. In an HCC827 xenograft model, combination treatment with DS-1205b and osimertinib significantly delayed on the onset of tumor resistance compared to osimertinib alone in a manner proportional to DS-1205b dose. DS-1205b also showed a similar resistance delay effect in combination with erlotinib or gefitinib in the same xenograft model. AXL up-regulation was associated with the development of resistance to erlotinib or gefitinib treatment in another HCC827 xenograft study, and DS-1205b restored the antitumor activity of erlotinib in erlotinib-resistant tumors in a dose-dependent manner. Combination treatment of DS-1205b with osimertinib, erlotinib, or gefitinib delayed the onset of resistance in acquired-resistance models using HCC827, and among these three models, the delay of resistance onset with DS-1205b was observed to be greatest in the osimertinib model. AXL and some EMT-related genes were up-regulated in EGFR-TKI-resistant tumors, while cell cycle, migration, or angiogenesis factors were down-regulated by treatment of those tumors with combination of DS-1205b and EGFR-TKI. In an HCC827 xenograft model of EGFR-mutant NSCLC, inhibition of AXL activity by DS-1205b restored sensitivity to erlotinib, and addition of DS-1205b to osimertinib delayed the onset of resistance to osimertinib. These findings support further non-clinical and clinical studies targeting inhibition of AXL in EGFRm NSCLC. A phase I study in combination with osimertinib is ongoing, and its design is shown in a separate presentation." @default.
• W2767476799 created "2017-11-17" @default.
• W2767476799 creator A5002627550 @default.
• W2767476799 creator A5002744884 @default.
• W2767476799 creator A5019542578 @default.
• W2767476799 creator A5021421264 @default.
• W2767476799 creator A5026726115 @default.
• W2767476799 creator A5038238652 @default.
• W2767476799 creator A5043627463 @default.
• W2767476799 creator A5045577515 @default.
• W2767476799 creator A5046850837 @default.
• W2767476799 creator A5054574919 @default.
• W2767476799 creator A5056496717 @default.
• W2767476799 creator A5059940480 @default.
• W2767476799 creator A5074327253 @default.
• W2767476799 date "2017-11-01" @default.
• W2767476799 modified "2023-09-27" @default.
• W2767476799 title "P3.02-042 DS-1205b, a Novel, Selective, Inhibitor of AXL, Delays the Onset of Resistance and Overcomes Acquired Resistance to EGFR-TKIs" @default.
• W2767476799 doi "https://doi.org/10.1016/j.jtho.2017.09.1571" @default.
• W2767476799 hasPublicationYear "2017" @default.
• W2767476799 type Work @default.
• W2767476799 sameAs 2767476799 @default.
• W2767476799 citedByCount "1" @default.
• W2767476799 countsByYear W27674767992020 @default.
• W2767476799 crossrefType "journal-article" @default.
• W2767476799 hasAuthorship W2767476799A5002627550 @default.
• W2767476799 hasAuthorship W2767476799A5002744884 @default.
• W2767476799 hasAuthorship W2767476799A5019542578 @default.
• W2767476799 hasAuthorship W2767476799A5021421264 @default.
• W2767476799 hasAuthorship W2767476799A5026726115 @default.
• W2767476799 hasAuthorship W2767476799A5038238652 @default.
• W2767476799 hasAuthorship W2767476799A5043627463 @default.
• W2767476799 hasAuthorship W2767476799A5045577515 @default.
• W2767476799 hasAuthorship W2767476799A5046850837 @default.
• W2767476799 hasAuthorship W2767476799A5054574919 @default.
• W2767476799 hasAuthorship W2767476799A5056496717 @default.
• W2767476799 hasAuthorship W2767476799A5059940480 @default.
• W2767476799 hasAuthorship W2767476799A5074327253 @default.
• W2767476799 hasBestOaLocation W27674767991 @default.
• W2767476799 hasConcept C121608353 @default.
• W2767476799 hasConcept C126322002 @default.
• W2767476799 hasConcept C143998085 @default.
• W2767476799 hasConcept C2776256026 @default.
• W2767476799 hasConcept C2777626846 @default.
• W2767476799 hasConcept C2777930144 @default.
• W2767476799 hasConcept C2778087573 @default.
• W2767476799 hasConcept C2778820342 @default.
• W2767476799 hasConcept C2779438470 @default.
• W2767476799 hasConcept C2780580887 @default.
• W2767476799 hasConcept C502942594 @default.
• W2767476799 hasConcept C71924100 @default.
• W2767476799 hasConceptScore W2767476799C121608353 @default.
• W2767476799 hasConceptScore W2767476799C126322002 @default.
• W2767476799 hasConceptScore W2767476799C143998085 @default.
• W2767476799 hasConceptScore W2767476799C2776256026 @default.
• W2767476799 hasConceptScore W2767476799C2777626846 @default.
• W2767476799 hasConceptScore W2767476799C2777930144 @default.
• W2767476799 hasConceptScore W2767476799C2778087573 @default.
• W2767476799 hasConceptScore W2767476799C2778820342 @default.
• W2767476799 hasConceptScore W2767476799C2779438470 @default.
• W2767476799 hasConceptScore W2767476799C2780580887 @default.
• W2767476799 hasConceptScore W2767476799C502942594 @default.
• W2767476799 hasConceptScore W2767476799C71924100 @default.
• W2767476799 hasIssue "11" @default.
• W2767476799 hasLocation W27674767991 @default.
• W2767476799 hasOpenAccess W2767476799 @default.
• W2767476799 hasPrimaryLocation W27674767991 @default.
• W2767476799 hasRelatedWork W2618138083 @default.
• W2767476799 hasRelatedWork W2822334320 @default.
• W2767476799 hasRelatedWork W2904848906 @default.
• W2767476799 hasRelatedWork W2908855951 @default.
• W2767476799 hasRelatedWork W2921871143 @default.
• W2767476799 hasRelatedWork W2955437186 @default.
• W2767476799 hasRelatedWork W2968906555 @default.
• W2767476799 hasRelatedWork W3000070469 @default.
• W2767476799 hasRelatedWork W3213033493 @default.
• W2767476799 hasRelatedWork W4310753260 @default.
• W2767476799 hasVolume "12" @default.
• W2767476799 isParatext "false" @default.
• W2767476799 isRetracted "false" @default.
• W2767476799 magId "2767476799" @default.
• W2767476799 workType "article" @default.